Advertisement

Advertisement

Colorectal Cancer
Symptom Management

Potential Factors in Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage III Colon Cancer

In an analysis from the phase III CALGB (Alliance)/SWOG 80702 trial of adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for patients with stage III colon cancer reported in the Journal of Clinical Oncology, Lee et al found that longer duration of oxaliplatin treatment was associated with ...

Breast Cancer
Colorectal Cancer

Importance of Screening Programs in Diagnosing Cancer in Patients With Type 2 Diabetes

Researchers have discovered that patients with type 2 diabetes who develop cancer are more likely to be diagnosed with advanced disease if they do not undergo routine screenings, according to a new study published by Jansana et al in the European Journal of Cancer. The new findings were also...

Colorectal Cancer

The NordICC Trial: The Devil Is in the Details

Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 150,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people older than age 50, which is...

Colorectal Cancer

Moderate Exercise May Help Reduce Inflammation, Increase Survival in Patients With Colorectal Cancer by Improving Gut Microbiota

After examining the impact of exercise on the gut microbiome of patients with cancer and reporting a positive association, researchers discovered that regular physical activity may extend the survival of patients with colorectal cancer, according to a new study published by Himbert et al in the...

Colorectal Cancer

Nationwide Study Finds Higher Rates of Cancer Mortality, Increasing Cases of Early-Onset Colorectal Cancer Among American Indian and Alaska Native Individuals

New findings revealed that overall cancer mortality among American Indian and Alaska Native patients was 18% higher than among White patients despite similar cancer incidence, according to a new study published by Kratzer et al in CA: A Cancer Journal for Clinicians. The findings included the first ...

Colorectal Cancer

Early Discontinuation of Full Treatment Regimen or Oxaliplatin Alone in Patients Receiving Adjuvant Oxaliplatin/Fluoropyrimidine Therapy for Stage III Colon Cancer

In a pooled analysis reported in the Journal of Clinical Oncology, Gallois et al found that early discontinuation of adjuvant oxaliplatin/fluoropyrimidine regimens—consisting of  FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin)—was associated...

Colorectal Cancer

Prevalence of Mismatch Repair Deficiency in Rectal Adenocarcinoma in a Prospective Screening Program

As reported in a letter published in The New England Journal of Medicine by Papke et al, data from a prospective biopsy screening program at a large gastrointestinal pathology group indicate that approximately 3% of rectal adenocarcinomas are mismatch repair (MMR)-deficient. Study Background As...

Colorectal Cancer

Phase III FRESCO-2 Trial of Fruquintinib Meets Primary Endpoint in Metastatic Colorectal Cancer

HUTCHMED (China) Limited recently announced that the global phase III FRESCO-2 trial evaluating the investigational use of the anti–vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory...

Colorectal Cancer

Effect of Invitation to Colonoscopy Screening on Risk of Colorectal Cancer and Risk of Mortality: The NordICC Trial

In a pragmatic trial reported in The New England Journal of Medicine, Bretthauer et al, on behalf of the Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group, found a reduced risk of colorectal cancer diagnosis but no significant reduction in disease-specific mortality among...

Colorectal Cancer

NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer

Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...

Colorectal Cancer

The NordICC Trial: The Devil Is in the Details

Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...

Issues in Oncology
Breast Cancer
Gynecologic Cancers
Colorectal Cancer

Use of Remote Interventions Increased Adherence to Cancer Screenings Among Women in Rural Areas

Studies show that rural populations experience greater cancer disparities across the cancer control continuum—from prevention and incidence to survivorship and mortality—compared with their urban counterparts. Those living in rural parts of the United States also tend to have lower cancer screening ...

Colorectal Cancer

Study Examines Efficacy, Cost of FIT vs Multitarget Stool DNA Testing for Colorectal Cancer Screening

Commercially available noninvasive screening tests for colorectal cancer—the fecal immunochemical test (FIT) and the Cologuard multitarget stool DNA test—are equally effective for screening patients with early-stage colorectal cancer. However, FIT costs about one-fifth of the multitarget stool DNA...

Colorectal Cancer

Timely Surveillance With Chest Imaging May Benefit Patients With Metastatic Colorectal Cancer

Patients with colorectal cancer who have certain clinical characteristics may benefit from more frequent chest imaging to help identify and target cancer that has metastasized to the lungs, according to a new study presented at the 2022 Scientific Forum of the American College of Surgeons Clinical...

Colorectal Cancer

Researchers Discover Predictive Biomarker of Response to Therapy in Patients With Microsatellite-Stable Metastatic Colorectal Cancer

Researchers have unmasked mutations in the RNF43 gene as predictive biomarkers of a response to treatment with anti-BRAF/EGFR combination therapy in patients with microsatellite-stable BRAF V600E–mutated metastatic colorectal cancer. Data showed that patients with tumors harboring loss-of-function...

colorectal cancer

S.M. Qasim Hussaini, MD, on Colon Cancer Treatment Outcomes and Historical Housing Discrimination

S. M. Qasim Hussaini, MD, of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, discusses findings from a nationwide study of the association between living in areas with discriminatory mortgage practices from the 1930s with present-day access to quality colon cancer care. The study underscores the importance of state- and federal-level practices on mortgage lending regulation and fair housing practices in determining equitable cancer risk, access to care, and outcomes (Abstract 69).

Breast Cancer
Gynecologic Cancers
Colorectal Cancer
Issues in Oncology

Effect of Social Factors on Cancer Screening Rates Across U.S. Counties

Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...

Colorectal Cancer

NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer

Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...

Colorectal Cancer
Geriatric Oncology

Treatments and Outcomes for Locally Advanced Rectal Cancer in Patients Aged 80 and Older

In an analysis of National Cancer Database data reported in JAMA Surgery, Nassoiy et al found that neoadjuvant chemoradiation therapy followed by surgery was associated with higher rates of R0 resection and improved survival vs other treatments in patients aged 80 and older undergoing surgery for...

Colorectal Cancer

Historical Housing Discrimination May Adversely Affect Contemporary Colon Cancer Care and Outcomes

Recent findings showed that historical housing discrimination may negatively affect contemporary care and outcomes for patients diagnosed with colon cancer, according to a study by Hussaini et al in the Journal of Clinical Oncology. The findings were also presented at the 2022 ASCO Quality Care...

colorectal cancer
immunotherapy

Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patients with deficient DNA mismatch–repair microsatellite-instability metastatic colorectal cancer. According to Dr. Taïeb, the study indirectly suggests this population should be treated as soon as possible with an immune checkpoint inhibitor (Abstract LBA23).

Colorectal Cancer

Study Shows Many Patients Prefer Stool Test to Colonoscopy for Colorectal Cancer Screening

Three-quarters of surveyed people preferred to do a fecal immunochemical test (FIT) rather than undergo a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study published by Makaroff et al in Clinical Gastroenterology and Hepatology. “One of the big issues...

Colorectal Cancer

Precision Physical Activity Prescriptions May Improve Survival in Patients With Stage III Colon Cancer

Physical activity may be associated with improved outcomes for patients undergoing postoperative treatment for stage III colon cancer, according to findings from a new study out of Pennington Biomedical Research Center published by Brown et al in the Journal of Clinical Oncology. The study assessed ...

colorectal cancer

MSI-High Rectal Adenocarcinoma

This is Part 4 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the management of microsatellite instability (MSI)-high rectal adenocarcinoma. The patient is a 62-year-old man with a large fungating nonobstructive tumor 6 cm from the anal verge, which is invading the mesorectum, and with enlarged mesorectal and superior hemorrhoidal lymph nodes. Immunohistochemistry reveals a dMMR tumor with loss of MLH1/PMS2, MLH1 promotor hypermethylation, and a BRAF V600E mutation. The faculty discuss next steps for this patient, including the current standard of care of trimodality therapy for locally advanced rectal adenocarcinoma, as well as ongoing trials that are evaluating the possibility of de-escalating trimodality therapy by omitting radiation or surgery.

colorectal cancer

HER2-Positive Colorectal Cancer

This is Part 3 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the management of HER2-positive colorectal cancer. The patient is a 45-year-old man who presents to the clinic with diarrhea, constipation, and periodic blood in his stool over the past 6 months. Colonoscopy reveals a nonobstructing tumor 16 cm from the anal verge, and CT scans reveal bilateral liver metastases with a primary rectosigmoid cancer with bulky adenopathy, as well as nonspecific subcentimeter lung nodules. After starting a course of FOLFOXIRI and bevacizumab, next-generation sequencing reveals that the patient is HER2-positive. The faculty discuss the next steps for this patient in light of the recent MOUNTAINEER trial and discuss the role of HER2 positivity in colorectal cancer.

colorectal cancer

Role of Neoadjuvant Therapy in T4 Colon Cancer

This is Part 2 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the role of neoadjuvant therapy in T4 colon cancer. The patient a 65-year-old woman who is diagnosed with a moderately differentiated adenocarcinoma with a partial mismatch repair mutation; flexible sigmoidoscopy reveals an ulcerating fungating lesion about 20 cm from the anal verge, and CT scans show no evidence of distant metastatic disease. The faculty discuss the next treatment options for this patient, given that patients with T4 tumors typically have higher risk of recurrence. Dr. Krishnamurthi reviews the findings of the FOxTROT and OPTICAL trials, which evaluated preoperative chemotherapy in T4 colon cancer. The faculty also discuss the potential role of preoperative immunotherapy for pMMR colon cancer.

colorectal cancer

Role of Circulating Tumor DNA in Early-Stage Colon Cancer

This is Part 1 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the role of circulating tumor DNA (ctDNA) in early-stage colon cancer. The patient is a 48-year-old woman with low-risk stage II colon cancer who underwent right hemicolectomy with no signs of metastasis. Immunohistochemistry revealed intact mismatch repair protein expression, and circulating tumor DNA was negative. She presents to the clinic asking about the best course of action after her surgery. The faculty discuss the role of ctDNA in guiding therapy in patients with low-risk colon cancer in light of the recent DYNAMIC, CIRCULATE-Japan, and GALAXY studies.

Colorectal Cancer

Association of Distance to Treatment Facility, U.S. Region, and Insurance Status With Diagnosis of Advanced Colon Cancer

In a National Cancer Database analysis reported in JAMA Network Open, Brand et al found that patients with colon cancer who lived farther from their treatment facility and those with no insurance or Medicaid alone were more likely to present with advanced-stage disease. As stated by the...

Colorectal Cancer
Genomics/Genetics

ctDNA Analysis of Acquired EGFR Resistance Alterations With First-Line Cetuximab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

In a circulating tumor DNA (ctDNA) substudy from the CALGB/SWOG-80405/Alliance trial reported in the Journal of Clinical Oncology, Kanwal Raghav, MD, MBBS, and colleagues found that first-line use of the anti-EGFR antibody cetuximab combined with chemotherapy was associated with only a small number ...

Colorectal Cancer

Recurrence-Free Survival as Surrogate for Overall Survival in Patients Undergoing Resection of Colorectal Liver Metastases

In a single-center retrospective study and a separate meta-analysis reported in The Lancet Oncology, Ecker et al found low correlations between recurrence-free survival and overall survival among patients undergoing resection of colorectal cancer liver metastases. As stated by the investigators,...

Cost of Care
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer

Costs of Cancer Treatment for Younger, Privately Insured Patients

A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...

Colorectal Cancer

Use of Trimodality Therapy in Stage II/III Rectal Cancer in the United States: 10-Year Period

In a retrospective cohort study reported in JAMA Oncology, Hagen F. Kennecke, MD, and colleagues found that among U.S. patients with clinical stage II/III rectal cancer diagnosed between 2006 and 2016 who received trimodality therapy, use of postoperative chemoradiation therapy (CRT) decreased and...

Colorectal Cancer
Genomics/Genetics

Acquired EGFR Inhibitor Resistance Alterations Identified in ctDNA Analysis in Patients With Refractory Metastatic Colorectal Cancer

In a study reported in the Journal of Clinical Oncology by Topham et al, circulating tumor DNA (ctDNA) analysis indicated significantly increased frequencies of multiple potential EGFR inhibitor resistance alterations among patients with refractory metastatic colorectal cancer with vs without prior ...

Colorectal Cancer
Immunotherapy

Early Research Identifies Effective Combination Immunotherapy for Subgroup of Patients With Metastatic Colorectal Cancer

A physician-scientist at City of Hope has identified a novel combination immunotherapy regimen—a triplet therapy consisting of regorafenib, ipilimumab, and nivolumab—that demonstrated significant response in patients with chemotherapy-resistant, microsatellite-stable metastatic colorectal cancer....

Colorectal Cancer

FRESCO-2: Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer

Researchers reported study results showing that fruquintinib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR), significantly improved overall survival and progression-free survival in patients with refractory metastatic colorectal cancer. Findings...

Colorectal Cancer

Updated Results From the KRYSTAL-1 Study of Adagrasib in Advanced KRAS G12C–Mutated Colorectal Cancer

Updated results from KRYSTAL-1, a multicohort phase I/II study, evaluating adagrasib—an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS G12C—with or without cetuximab in patients with advanced colorectal cancer harboring a KRAS G12C mutation were presented by...

colorectal cancer

Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab

Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined subgroups of patients with initially unresectable colorectal cancer liver metastases and left-sided and RAS/BRAF V600E wild-type tumor. The study compared FOLFOX/FOLFIRI plus either bevacizumab or panitumumab (Abstract LBA21).  

Colorectal Cancer

New Risk Stratification System for Completely Resected Stage II or III Colorectal Cancer

As reported in The Lancet Oncology, Kleppe et al have developed a risk stratification system using the DoMore-v1-CRC marker and pathologic staging markers that may permit many patients with stage II or III colorectal cancer to avoid adjuvant chemotherapy. As stated by the investigators, “The...

Colorectal Cancer
Immunotherapy

Expert Point of View: Ryan B. Corcoran, MD, PhD

Ryan B. Corcoran, MD, PhD, commented on the C-800 study for The ASCO Post. Dr. Corcoran is the Mark J. Kusek Endowed Chair in Colorectal Cancer, Director of the Gastrointestinal Cancer Center Program and Scientific Director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital...

Colorectal Cancer
Immunotherapy

Activity Shown for Novel Immunotherapy Combination in Microsatellite-Stable Colorectal Cancer

Expanded data from the phase I C-800 study showed the immunotherapy combination of botensilimab and balstili­mab appeared to be active in patients with microsatellite-stable (MSS) metastatic colorectal cancer. The findings were reported at the European Society for Medical Oncology (ESMO) World...

Colorectal Cancer

Neoadjuvant Chemotherapy and Organ-Preserving Surgery in Early Rectal Cancer

As reported in the Journal of Clinical Oncology by Hagen F. Kennecke, MD, MHA, and colleagues, the Canadian Cancer Trials Group phase II NEO trial has shown that 3 months of neoadjuvant chemotherapy resulted in tumor downstaging and avoidance of radical surgery in a high proportion of patients with ...

Colorectal Cancer

Addition of Galunisertib to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

In a small phase II trial reported in The Lancet Oncology, Yamazaki et al found that the TGF-β type I receptor kinase inhibitor galunisertib appeared to show activity when added to neoadjuvant chemoradiation in previously untreated patients with locally advanced rectal cancer. As stated by the...

Colorectal Cancer

Study Shows AI May Improve Prediction of Colorectal Cancer Recurrence

In a multinational study using artificial intelligence (AI), investigators developed an algorithm to improve the prediction of colorectal cancer recurrence. Study results were published by Pai et al in Gastroenterology. QuantCRC Rish K. Pai, MD, PhD, a pathologist at Mayo Clinic in Arizona and...

Colorectal Cancer

Effect of Physical Activity on Disease-Free Survival in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer

As reported in the Journal of Clinical Oncology by Brown et al, a prospective cohort study nested within the phase III CALGB/SWOG 80702/Alliance trial showed that greater volumes of physical activity in patients receiving adjuvant therapy for stage III colon cancer were associated with significant...

Colorectal Cancer

Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis

Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...

Issues in Oncology
Colorectal Cancer

Models to Assess Impact of Centralization of Specialist Cancer Services in England

In a study reported in The Lancet Oncology, Aggarwal et al identified the impact of several models of centralization of specialist cancer services in England, using rectal cancer surgery as an example. As stated by the investigators, “Centralization of specialist cancer services is occurring in...

Colorectal Cancer

MOUNTAINEER: Tucatinib Plus Trastuzumab Active in Metastatic Colorectal Cancer

In the phase II MOUNTAINEER trial, tucatinib in combination with trastuzumab produced durable responses in patients with previously treated HER2-positive metastatic colorectal cancer. The late-breaking data were presented at the European Society for Medical Oncology (ESMO) World Congress on...

Colorectal Cancer

Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Evaluation of Fruquintinib for Metastatic Colorectal Cancer

The pivotal global phase III FRESCO-2 trial evaluating the investigational use of fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for the...

Colorectal Cancer

Duration of Adjuvant Oxaliplatin With 6 Months of Fluoropyrimidine Treatment in High-Risk Stage II or III Colorectal Cancer

In a Korean phase III noninferiority trial (KCSG CO09-07) reported in the Journal of Clinical Oncology, Kim et al found noninferiority in disease-free survival and reduced risk of neuropathy for adjuvant therapy with 3 vs 6 months of oxaliplatin plus 6 months of fluoropyrimidine treatment in...

Colorectal Cancer

Cathy Eng, MD, FACP, FASCO, Comments on Findings From CAIRO5

The invited discussant of the CAIRO5 presentation at the 2022 ASCO Annual Meeting was Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology, and Oncology at Vanderbilt-Ingram Cancer Center, Nashville. Dr. Eng explained the key questions being asked by the investigators. “If you have a...

Advertisement

Advertisement

Advertisement